RWD Study in HER2+ mBC Patients in Third-Line Therapy

CompletedOBSERVATIONAL
Enrollment

63

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

May 30, 2021

Study Completion Date

May 30, 2021

Conditions
Breast Cancer Stage IV
Interventions
OTHER

No intervention

retrospective chart review study

Trial Locations (8)

Unknown

Centre hospitalier universitaire Dr-Georges-L.-Dumont, Moncton

The Moncton Hospital, Moncton

The Ottawa Hospital, Ottawa

Sunnybrook Health Center, Toronto

CHUM- Centre hospitalier de l'universite de Montreal, Montreal

Jewish General Hospital, Montreal

CHUQ- Centre hospitalier universitaire de Québec, Québec

CHUS-CIUSSS de l'Estrie - CHUS - Hôtel-Dieu and CHUS - Hôpital Fleurimont, Sherbrooke

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Knight Therapeutics

UNKNOWN

lead

Exactis Innovation

OTHER

NCT04566458 - RWD Study in HER2+ mBC Patients in Third-Line Therapy | Biotech Hunter | Biotech Hunter